A detailed history of Excalibur Management Corp transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Excalibur Management Corp holds 32,859 shares of BMY stock, worth $1.9 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
32,859
Previous 31,641 3.85%
Holding current value
$1.9 Million
Previous $1.31 Million 29.38%
% of portfolio
0.65%
Previous 0.54%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $48,305 - $63,031
1,218 Added 3.85%
32,859 $1.7 Million
Q2 2024

Aug 09, 2024

BUY
$40.25 - $52.99 $249,509 - $328,485
6,199 Added 24.37%
31,641 $1.31 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $159,245 - $180,553
3,319 Added 15.0%
25,442 $1.38 Million
Q4 2023

Feb 12, 2024

BUY
$48.48 - $57.85 $52,649 - $62,825
1,086 Added 5.16%
22,123 $1.14 Million
Q3 2023

Nov 09, 2023

BUY
$57.89 - $64.73 $67,210 - $75,151
1,161 Added 5.84%
21,037 $1.22 Million
Q2 2023

Aug 08, 2023

BUY
$63.71 - $70.74 $3,504 - $3,890
55 Added 0.28%
19,876 $1.27 Million
Q1 2023

May 05, 2023

BUY
$65.71 - $74.53 $20,238 - $22,955
308 Added 1.58%
19,821 $1.37 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $40,266 - $47,680
-588 Reduced 2.93%
19,513 $1.4 Million
Q3 2022

Nov 04, 2022

BUY
$0.13 - $76.84 $1 - $998
13 Added 0.06%
20,101 $1.43 Million
Q2 2022

Jul 25, 2022

SELL
$72.62 - $79.98 $278,352 - $306,563
-3,833 Reduced 16.02%
20,088 $1.55 Million
Q1 2022

May 03, 2022

SELL
$61.48 - $73.72 $5,594 - $6,708
-91 Reduced 0.38%
23,921 $1.75 Million
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $202,989 - $236,638
3,785 Added 18.71%
24,012 $1.5 Million
Q3 2021

Oct 28, 2021

BUY
$59.17 - $69.31 $75,145 - $88,023
1,270 Added 6.7%
20,227 $1.2 Million
Q2 2021

Jul 26, 2021

BUY
$61.91 - $67.42 $12,382 - $13,484
200 Added 1.07%
18,957 $1.27 Million
Q1 2021

May 03, 2021

BUY
$59.34 - $66.74 $53,287 - $59,932
898 Added 5.03%
18,757 $1.18 Million
Q4 2020

Jan 26, 2021

BUY
$57.74 - $65.43 $24,424 - $27,676
423 Added 2.43%
17,859 $1.11 Million
Q3 2020

Nov 02, 2020

SELL
$57.43 - $63.64 $9,533 - $10,564
-166 Reduced 0.94%
17,436 $1.05 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $13,430 - $15,702
-245 Reduced 1.37%
17,602 $1.04 Million
Q1 2020

May 15, 2020

BUY
$46.4 - $67.43 $7,099 - $10,316
153 Added 0.86%
17,847 $995,000
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $11,318 - $14,763
230 Added 1.32%
17,694 $1.14 Million
Q3 2019

Oct 21, 2019

BUY
$42.77 - $50.71 $12,103 - $14,350
283 Added 1.65%
17,464 $886,000
Q2 2019

Jul 26, 2019

BUY
$44.62 - $49.34 $64,520 - $71,345
1,446 Added 9.19%
17,181 $779,000
Q1 2019

Apr 24, 2019

SELL
$45.12 - $53.8 $451 - $538
-10 Reduced 0.06%
15,735 $751,000
Q4 2018

Jan 29, 2019

SELL
$48.76 - $63.23 $38,032 - $49,319
-780 Reduced 4.72%
15,745 $818,000
Q3 2018

Oct 25, 2018

SELL
$55.19 - $62.25 $30,354 - $34,237
-550 Reduced 3.22%
16,525 $1.03 Million
Q1 2018

Apr 23, 2018

SELL
$59.92 - $68.98 $8,988 - $10,347
-150 Reduced 0.87%
17,075 $1.08 Million
Q4 2017

Jan 22, 2018

SELL
$59.94 - $65.35 $32,367 - $35,289
-540 Reduced 3.04%
17,225 $1.06 Million
Q3 2017

Oct 25, 2017

BUY
$55.23 - $63.74 $981,160 - $1.13 Million
17,765
17,765 $1.13 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Excalibur Management Corp Portfolio

Follow Excalibur Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Excalibur Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Excalibur Management Corp with notifications on news.